The Role for Comprehensive NGS Testing in Upper GI Cancers

Opinion
Video

Medical oncologists discuss the role for comprehensive next-generation sequencing (NGS) in upper GI cancers and the potential role for zolbetuximab.

Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Related Content
The addition of pelareorep to standard-of-care therapy in patients with KRAS-mutated microsatellite-stable CRC exhibited an ORR of 33%.

Pelareorep Exhibits Activity in Second-Line KRAS-Mutated Metastatic CRC

Roman Fabbricatore
December 16th 2025
Article

The addition of pelareorep to standard-of-care therapy in patients with KRAS-mutated microsatellite-stable CRC exhibited an ORR of 33%.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

The COMPASSION-37 study is the second international registrational study for cadonilimab following an ongoing trial in hepatocellular carcinoma.

FDA OKs Phase 3 Cadonilimab/Chemo Trial in HER2-Negative Gastric Cancer

Russ Conroy
December 12th 2025
Article

The COMPASSION-37 study is the second international registrational study for cadonilimab following an ongoing trial in hepatocellular carcinoma.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.

Laparoscopic Distal Gastrectomy Appears Feasible in T4a Gastric Cancer

Russ Conroy
December 3rd 2025
Article

Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.

Findings from the HERIZON-BTC-01 trial support HER2 as a valid therapeutic target in biliary tract cancer.

Zanidatamab Shows Meaningful Benefit in HER2+ Biliary Tract Cancer

Russ Conroy
December 1st 2025
Article

Findings from the HERIZON-BTC-01 trial support HER2 as a valid therapeutic target in biliary tract cancer.